Work

Novel Antiandrogen Arn-509 in High-Risk Non-Metastatic (M0) Castration-Resistant Prostate Cancer (Crpc)

Year: 2014

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu336.9

Authors: M.R. Smith, E.S. Antonarakis, C.J. Ryan, W. Berry, N.D. Shore, G. Liu, J. Alumkal, C. Higano, E. Chow-Maneval, R. Bandekar, C. De Boer, M. Todd, M. Yu, D.E. Rathkopf

Institutions: Harvard University, Massachusetts General Hospital, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Carolina Urologic Research Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, OHSU Knight Cancer Institute, University of Washington, Fred Hutch Cancer Center, Janssen (Netherlands), Janssen Research & Development (United States), Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Sanofi, Celgene, Astellas Pharma

OpenAlex ID: W2239656989

FWCI: 0.727

Cites:

Cited by: 4

Related to: 10